Intellia Therapeutics’ (NTLA) Buy Rating Reaffirmed at Chardan Capital

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “buy” rating restated by investment analysts at Chardan Capital in a research note issued to investors on Friday,Benzinga reports. They presently have a $26.00 price target on the stock. Chardan Capital’s target price would indicate a potential upside of 82.07% from the company’s current price.

NTLA has been the subject of a number of other research reports. Wells Fargo & Company reduced their target price on Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating for the company in a report on Friday, November 7th. Royal Bank Of Canada reduced their price objective on Intellia Therapeutics from $14.00 to $9.00 and set a “sector perform” rating for the company in a research note on Friday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Thursday, January 22nd. Wedbush reduced their target price on shares of Intellia Therapeutics from $9.00 to $7.00 and set a “neutral” rating for the company in a research report on Friday, November 7th. Finally, Oppenheimer set a $27.00 price target on shares of Intellia Therapeutics in a research note on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Intellia Therapeutics currently has an average rating of “Hold” and an average target price of $17.48.

Intellia Therapeutics Stock Performance

Shares of NASDAQ NTLA opened at $14.28 on Friday. Intellia Therapeutics has a 1 year low of $5.90 and a 1 year high of $28.25. The company’s fifty day moving average price is $11.80 and its 200 day moving average price is $13.00. The company has a market capitalization of $1.65 billion, a PE ratio of -3.34 and a beta of 2.10.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, beating the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The firm had revenue of $23.02 million during the quarter, compared to analyst estimates of $12.17 million. During the same quarter in the previous year, the business earned ($1.27) EPS. Intellia Therapeutics’s revenue for the quarter was up 78.4% compared to the same quarter last year. On average, equities analysts expect that Intellia Therapeutics will post -5.07 EPS for the current year.

Insider Activity

In other news, CEO John M. Leonard sold 34,146 shares of the company’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $314,484.66. Following the transaction, the chief executive officer owned 1,013,339 shares of the company’s stock, valued at $9,332,852.19. This represents a 3.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the sale, the executive vice president directly owned 98,533 shares of the company’s stock, valued at $907,488.93. The trade was a 7.95% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 53,051 shares of company stock valued at $488,600. 3.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Intellia Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NTLA. Caitong International Asset Management Co. Ltd acquired a new position in Intellia Therapeutics during the 3rd quarter worth approximately $30,000. Blue Bell Private Wealth Management LLC purchased a new position in Intellia Therapeutics in the third quarter valued at about $30,000. Advisory Services Network LLC purchased a new stake in shares of Intellia Therapeutics during the 3rd quarter worth approximately $33,000. Headlands Technologies LLC purchased a new stake in Intellia Therapeutics during the second quarter worth $26,000. Finally, Comerica Bank raised its position in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after acquiring an additional 901 shares during the last quarter. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Trending Headlines about Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Q4 results beat expectations — loss per share was smaller than expected and revenue nearly doubled year-over-year, signaling commercial/partner progress and giving the stock an immediate bullish trigger. Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
• Positive Sentiment: FDA lifted the clinical hold on MAGNITUDE‑2 and management laid out 2026 plans for lonvo‑z (HAE), including expected Phase 3 readout timing, BLA timing and a targeted U.S. launch window — this materially de‑risks a key commercial program. Intellia outlines 2026 lonvo-z launch plans as FDA lifts clinical hold on MAGNITUDE-2
• Positive Sentiment: Balance sheet strength — Intellia ended 2025 with roughly $605M in cash and marketable securities, which supports ongoing trials and commercial preparation into pivotal readouts. Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
• Neutral Sentiment: Analyst model updates from Brookline Capital show continued 2026 quarterly losses (multiple quarters forecast negative EPS), but the firm materially increased FY2028/FY2029 earnings projections — signaling high conviction in longer‑term commercial upside despite short‑term losses.
• Negative Sentiment: Company remains loss‑making with a negative net margin and negative ROE; consensus still expects a large full‑year 2026 loss (around -$5.07 EPS), which leaves the stock sensitive to execution and cash‑burn news. Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
• Negative Sentiment: Regulatory risk is not fully cleared — while MAGNITUDE‑2 hold was lifted, engagement is ongoing to resolve a hold on another MAGNITUDE trial (ATTR‑CM), keeping upside contingent on additional FDA interactions and successful re‑starts. Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates (Yahoo)

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.